GYRE Earnings Preview

Gyre acquires Cullgen for $300M to expand protein degrader platform

This acquisition expands Gyre's pipeline depth in a high-potential modality — protein degraders are an increasingly validated drug class with multiple late-stage candidates in development across the industry. The integration of Cullgen's China-based manufacturing capability strengthens supply-chain resilience while the all-stock structure preserves Gyre's cash for clinical development.

Watch: Monitor Q2 2026 closing progress and regulatory approval timelines. Watch for integration updates on manufacturing efficiency gains and updates on Cullgen's lead candidates moving through the clinic — these will telegraph whether Gyre can execute this expansion without derailing its own development timelines.